Delusional parasitosis (DP) is mostly described in single cases or small samples. Data on epidemiology, nosological classification, therapy and course are therefore difficult to interpret. A thorough literature review is recommended to delineate common features of the syndrome. All case reports concerning DP (except toxic forms) were collected and analyzed according to a standardized protocol. DP is a disorder which may occur in every period of life but is much more frequent in older subjects. Sex differences with a predominance of females increase with age. Mean duration of delusion was 3.0 ± 4.6 years (median: 1 year). Social isolation seems to be more a premorbid feature than a secondary phenomenon related to the delusion. Diagnostic classification revealed a high proportion of so-called ‘pure’ forms (‘delusional disorders’ in DSM-III-R or ICD-10) but the syndrome was also reported in schizophrenia, affective or organic psychosis or even as a neurotic symptom. Frequency of induced DP can be estimated between 5 and 15%. Course of DP is not so unfavorable as commonly thought; in about half the patients a full remission was described during the observation period or at catamnesis. Short preclinical courses may indicate better outcome. Comparing the patients of the prepsychopharmacological era (before 1960) with those after, the rate of full remissions increased from 33.9 to 51.9%.

Delusional parasitosis (DP) is associated in 5–15% with shared psychotic disorder (SPD). Little systematic information is available about this particular aspect of the syndrome. A thorough review of all published cases with DP was carried out. 68 case histories of SPD were identified (5.67%). The data of these patients were compared with those of their inducers (n = 44) and with the data of DP patients, who did not transfer their delusional beliefs to others (n = 1,155). Approximately 30% of the psychotic dyads were reported from public health departments. The sex ratio was balanced in the SPD group, but showed a clear preponderance of females in the other two groups. SPD patients and their inducers reported more frequently visual illusions or hallucinations and located the animals correspondingly upon the surface of the skin. No diagnostic differences were found between the inducers and those who had DP but did not induce SPD in others. Albeit 50% of the SPD patients did not receive any treatment except separation from the inducer, the remission rate in this group was 93%.

No abstract

The documentation of psychopathology is core to the clinical practice of the psychiatrist and clinical psychologist. However, both in initial as well as further training and specialization in their fields, this particular aspect of their work receives scanty attention only. Yet, for the past 50 years, the Association for Methodology and Documentation in Psychiatry (AMDP) System has been in existence and available as a tool to serve precisely the purpose of offering a systematic introduction to the terminology and documentation of psychopathology. The motivation for its development was based on the need for an assessment procedure for the reliable documentation of the effectiveness of newly developed psychopharmacological substances. Subsequently, the AMDP-System began to be applied in the context of investigations into a number of methodological issues in psychiatry (e.g., the frequency and specificity of particular symptoms, the comparison of rating scales). The System then became increasingly important also in clinical practice and, today, represents the most used instrument for the documentation of psychopathology in the German-speaking countries of Europe. This paper intends to offer an overview of the AMDP-System, its origins, design, and functionality. After an initial account of the history and development of the AMDP-System, the discussion will in turn focus on the System’s underlying methodological principles, the transfer of clinical skills and competencies in its practical application, and its use in research and clinical practice. Finally, potential future areas of development in relation to the AMDP-System are explored.

A 38-year-old patient with severe obsessive-compulsive disorder received fluvoxamine in a clinical study. Psychometric ratings showed marked clinical improvement in the third week of fluvoxamine administration, but after 8 weeks, at a dose of 300 mg per day, he suffered a grand mal seizure after drinking a glass of beer (0.2 liter). He had no history of previous epileptic seizures. Careful neurological evaluation including computer tomography and magnetic resonance imaging of the brain revealed no signs of acute disease. EEG before the fit did not show epileptiform activity; after the fit, spikes and spike-wave complexes appeared, which disappeared upon discontinuation of fluvoxamine. Since his obsessive-compulsive symptoms had responded well to fluvoxamine and worsened after its discontinuation, the drug was cautiously reintroduced. Improvement of the obsessive-compulsive symptoms was observed again, but spikes and spike-wave complexes reappeared at a dose of 50 mg per day. Under anticonvulsant treatment with carbamazepine, fluvoxamine was increased to 100 mg per day. No seizures occurred during a follow-up to two years.